Стовбурові клітини
| лікування | |
|---|---|
| Лікування стовбуровими клітинами | $21000 |



Cell Grand Clinic is a regenerative medicine practice in Osaka, Japan. It specializes in autologous adipose-derived stem cell therapy and exosome treatments. The team treats knee osteoarthritis, diabetes, and arteriosclerosis. Dr. Yuichi Wakabayashi founded the clinic in 2006. He completed research training at the U.S. National Institutes of Health. Dr. Wakabayashi has performed over 3,000 stem cell procedures. He is certified by the American Board of Regenerative Medicine.
The clinic operates under Japan's Act on the Safety of Regenerative Medicine. It holds 13 treatment plans accepted by the Ministry of Health. Cells are processed in a government-licensed Cell Processing Center. The team keeps cell viability above 95% before administration. Purity testing follows the ISCT global standard. Patients receive a Certificate of Quality for every batch. The clinic was named Top Regenerative Medicine Solution in APAC in 2026. Dr. Wakabayashi conducts consultations in English.

| лікування | |
|---|---|
| Лікування стовбуровими клітинами | $21000 |
| лікування | |
|---|---|
| Курс лікування власними стовбуровими клітинами | $19800 |
The clinic operates under Japan's Act on the Safety of Regenerative Medicine (ASRM). This framework requires the Ministry of Health, Labour and Welfare (MHLW) to review all treatment plans. The clinic holds 13 accepted MHLW provision plans, so every protocol meets national safety standards.
In 2026, Healthcare Business Review APAC recognized the facility as a Top Regenerative Medicine Solution in APAC. All cell handling occurs in government-licensed Cell Processing Centers (License: FA5250001). This licensing means manufacturing conditions meet strict pharmaceutical-grade standards for patient safety.
Quality control follows global standards set by the International Society for Cell & Gene Therapy (ISCT). Specialists use ISCT-standard surface marker testing to verify cell identity before administration. Each patient receives a Certificate of Quality. It documents batch-specific purity, potency, and safety results.
The practice specializes in autologous adipose-derived stem cell (ADSC) therapy. This method uses a patient's own fat tissue to harvest regenerative cells. Dr. Yuichi Wakabayashi has personally performed over 3,000 stem cell procedures throughout his career.
Specialists treat various conditions using these regenerative techniques:
The "Grand Stem Cell" program uses a structured cultivation process lasting about seven weeks. Cells are expanded to 100–200 million before infusion, depending on the protocol. The clinic only uses cells up to Passage 3 and keeps viability above 95% to preserve regenerative potency.
Additional options include stem cell culture supernatant (exosome) therapy and PRP. The clinic also offers fibroblast transplants for skin rejuvenation. These treatments can be combined in a single visit to address multiple health goals at once.
Cultivation protocols are developed through academic collaboration with Prof. Takahiro Ochiya of Tokyo Medical University. This partnership brings exosome biology and microRNA signaling research into clinical practice. The laboratory team conducts multi-marker purity testing on every cell batch.
Safety protocols include rigorous testing for contaminants before any administration. Specialists screen every batch for sterility, endotoxins, and mycoplasma. The clinic maintains end-to-end traceability, logging every step from fat tissue collection to final cell delivery.
Dr. Yuichi Wakabayashi personally conducts consultations for international patients in English. He is a PhD-qualified physician who completed research training at the U.S. National Institutes of Health (NIH). The clinic provides bilingual support in English and Japanese for clear communication throughout.
The treatment journey for international patients follows three steps:
Post-treatment care includes 6 and 12-month remote follow-up sessions. These check-ins let Dr. Wakabayashi monitor recovery and long-term outcomes after the patient returns home.
